Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU.

Autores de IDIVAL

• 

  Álvaro Díaz González

  Autor

• 

  Fernando Rivera Herrero

  Autor

Autores ajenos al IDIVAL

• Riveiro-Barciela M
• Carballal S
• Mañosa M
• Gallgo-Plazas J
• Cubiella J
• Jiménez-Fonseca P
• Varela M
• Menchén L
• Sangro B
• Fernández-Montes A
• Mesonero F
• Rodríguez-Gandía MÁ
• Londoño MC

Unidades

• INVESTIGACIÓN CLÍNICA Y TRASLACIONAL EN ENFERMEDADES DIGESTIVAS

  

  Investigador Responsable

  José Ignacio Fortea Ormaechea

• ONCOLOGÍA MÉDICA

  

  Investigador Responsable

  Fernando Rivera Herrero

Abstract

The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase in immune-related adverse events (irAEs). Gastrointestinal and liver events encompass hepatitis, colitis and upper digestive tract symptoms accounting for the most common irAEs, with incidence rates varying from 2 % to 40 %, the latter in patients undergoing combined ICIs therapy. Based on the current scientific evidence derived from both randomized clinical trials and real-world studies, this statement document provides recommendations on the diagnosis, treatment and prognosis of the gastrointestinal and hepatic ICI-induced adverse events.

Keywords

• Immunotherapy; Immune checkpoint inhibitors; Toxicity; Hepatitis; Colitis; Drug-induced liver injury; Immune-related adverse events; Diarrhea